元隆雅圖(002878.SZ):2023-2025年員工持股計劃之第二期員工持股計劃累計購買1.53萬股
格隆匯3月12日丨元隆雅圖(002878.SZ)公佈,根據《關於上市公司實施員工持股計劃試點的指導意見》《深圳證券交易所上市公司自律監管指引第1號——主板上市公司規範運作》等相關規定,現將公司2023-2025年員工持股計劃之第二期員工持股計劃(簡稱“本次員工持股計劃”)實施進展情況公吿如下:截至2025年3月12日,公司本次員工持股計劃通過二級市場購買公司股票合計15,300股,佔公司總股本的0.0059%,成交金額合計為242,804.00元,成交均價約為15.87元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.